Henan Province's first genetic testing kit GMP R & D and production base is completed and put into operation

Henan Province's first genetic testing kit GMP R & D and production base is completed and put into operation

The biopharmaceutical industry is the air outlet industry that the city clearly seized. Relying on the Talent and technology of the Institute of Calculation of the Institute of Calculation of the Chinese Academy of Sciences, Luoyang Zhongke GMP R & D and production bases established. The key projects that have started at present have the conditions for production and will provide important scientific and technological support for the development of the biomedical industry in our city.

In the past two days, the Luoyang Zhongke GMP R & D and production base in Luoyang Intelligent Technology Industry Park has completed the installation of production and testing equipment. Clinical research and development verification will be carried out with some hospitals in our city. With the orderly advancement of the project, it will become the first genetic testing kit GMP R & D and production base in our province.

Liu Jingjia, Deputy General Manager of the Chief Medical Officer of Luoyang Zhongke GMP R & D and production base: It is a tumor early test kit. It was detected before the tumor was detected before the imaging manifestation, that is, the tumor could be found in very early in the early stage. Such patients are usually difficult to find clinically because it has no symptoms in clinical practice. It was found through our test and was found to be found. After that, through some radical surgery, this kind of tumor patient can cure

Luoyang Zhongke GMP R & D and production base projects, planned a total investment of 120 million yuan, relying on the strength of the Chinese Academy of Sciences Calculation Institute of Digital Economy Industry Research Institute and China Science Medicine (Hangzhou) Technology Co., Ltd. Points, build tumor biological sample libraries, health medical databases, GMP production workshops, and hospital inspection laboratories, and create an in vitro diagnostic kit from R & D, production, registration to listing and sales.

Liu Jingjia, deputy general manager of the chief medical officer of Luoyang Zhongke GMP R & D and production base: This kind of project is relatively large in the early stage, but the later output is very high, because its profit is very high, it can reach 40%of pure profits Essence This market is very large, just like a kit of bowel cancer, it is a 10 billion market each year. No company in Henan can do this.

In the "Fourteenth Five -Year Plan", our city will focus on key areas such as Chinese medicine, animal vaccine, medical equipment, and health services, and strengthen strategic cooperation with the industry's top R & D institutions and well -known universities to make up for the industrial technology development chain. Focusing on the five major fields, such as the traditional Chinese medicine industry, we will make new breakthroughs in industrial scale and technological level in the advantages areas, creating a new highland of important biomedical mid -high -end innovation research and development bases, industrial transformation applications and health services. Strive for 2025, the city's biomedical industry chain will be more complete, and the overall scale of the industry will reach 30 billion yuan.

Responsible editor: Shi Jian | Audit: Li Zhen | Director: Wan Junwei

- END -